Ultime notizie per Immutep (NASDAQ:IMMP) Azioni

Immutep

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.

Immutep Limited - American Depositary Shares

Immutep Ltd

Press Releases

Immutep Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

Patient Enrolment Completed for INSIGHT-003

Patient Enrolment Completed for EFTISARC-NEO Phase II Trial

Immutep Quarterly Activities Report Q2 FY25

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025

First Patient Dosed in Immutep's TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

Immutep to Participate in Upcoming Investor Conferences

IMMP

Abeona Therapeutics

Anika Therapeutics

Astria Therapeutics

Candel Therapeutics

Cidara Therapeutics

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

Cargo Therapeutics

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Design Therapeutics

Emergent BioSolutions

Foghorn Therapeutics

Humacyte

ITeos Therapeutics

Monopar Therapeutics

Nuvectis Pharma

Ocugen

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

AVITA Medical

Acelyrin

Taysha Gene Therapies, Inc. - Common Stock

Taysha Gene Therapies

2seventy bio

Vanda Pharmaceuticals Inc. - Common Stock

Vanda Pharmaceuticals

XOMA Royalty

Y-mAbs Therapeutics

Baird

Capital One

Maxim Group

Comments

Immutep

Notizie

Ultime notizie per Immutep (NASDAQ:IMMP) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO